Drug Profile
Testosterone gel - Biolab Sanus Farmaceutica
Latest Information Update: 30 Aug 2023
Price :
$50
*
At a glance
- Originator Biolab Sanus Farmaceutica
- Class Anabolic steroids; Androstenols; Erectile dysfunction therapies; Hormonal replacements; Small molecules; Testosterone congeners
- Mechanism of Action Testosterone agonists; Testosterone congener stimulants; Testosterone replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Menopausal syndrome
Most Recent Events
- 30 Aug 2023 Discontinued - Preclinical for Menopausal syndrome in Brazil (Topical) (Biolab Sanus Farmaceutica pipeline, August 2023)
- 28 Mar 2020 No recent reports of development identified for preclinical development in Menopausal-syndrome in Brazil (Topical, Gel)
- 01 May 2018 Biolab Sanus Farmaceutica withdraws a phase I trial in Menopausal syndrome (in post-menopausal women) in Brazil prior to enrolment (Topical) (NCT02667561)